Frank Zheng, managing director of JPI, said: “Our new product development strategy is expected to provide at least an additional six new products to the company’s existing family of strong selling products over the next 36 months. JPI is regularly reviewing various other product in-licensing opportunities.”
JPI is accelerating its new product development process beyond the nine new products that have already been announced. It currently has two products under review by the SFDA (China state food and drug administration): AMDL’s DR-70 cancer diagnostic test kit and docetaxel injectables. Both products are anticipated to be approved for sale in China during mid-2008.
Mr Dreher said: “In order for JPI to manufacture the docetaxel injectable product, it will be required to build a segregated product line over approximately the next 12 months.”
Four other products are in an R&D phase, including EO-H, a herbal treatment to improve bone density, TouJin NiangShi, a herbal liver cancer treatment, and drotaverrine hydrochloric and diammonium glycyrrhizinate, which are both chemotherapy therapeutic products. All four products are currently expected to gain SFDA approval within the next 24-36 months.